A CanaRx representative said he was baffled by the action, saying it facilitates sales of “American brand-name drugs only.”
By Lenny Bernstein and Lenny Bernstein Reporter covering health and medicine Email Bio Follow Laurie McGinley Laurie McGinley Reporter covering health and medicine Email Bio Follow February 28 at 4:20 PM The Food and Drug Administration issued an unusual warning letter Thursday to a Canadian drug distributor, contending the company has sent “unapproved” and “misbranded” drugs to consumers in the United States, jeopardizing their safety.
FDA Commissioner Scott Gottlieb said in an interview that the move “isn’t timed with anything. This isn’t politically motivated. This is our bread and butter. This is public health protection 101.” Morris, however, said the company facilitates only the sale of medicine made by brand-name companies such as Pfizer and Merck licensed by the FDA — in the original packaging. He said individual consumers submit prescriptions from U.S. doctors. Those are rewritten by doctors in Canada, Britain and Australia and filled by bricks-and-mortar pharmacies in those countries, he said. The drugs are then mailed to consumers, who pay, on average, 30 percent of the price they pay here.
The FDA said it has no reports of adverse reactions to drugs supplied by CanaRx. Rather, Gottlieb said in the interview, the FDA has tried to persuade CanaRx to reform practices that it contends allow counterfeit, adulterated, weak, super-potent and mislabeled drugs into the United States.
Australia Latest News, Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA warns against using surgical robots for breast cancer surgeryThe FDA warned patients and health care providers about using robotically assisted surgical devices for mastectomies and other cancer surgeries because of 'preliminary' evidence that it may be linked to lower long-term survival.
Read more »
Cannabis stocks mostly higher after FDA head promises April talks on CBD regulationCannabis stocks were mostly higher Thursday, as investors digested the latest earnings reports from the sector and comments from the head of the U.S. Food and Drug Administration on plans for regulation of CBD.
Read more »
U.S. Senator Sanders urges FDA to allow older versions of $375,000 drugU.S. Senator Bernie Sanders this week urged regulators to allow pharmacies and m...
Read more »
'Young blood' infusion company Ambrosia halts patient treatments after FDA warningThe FDA warned consumers against infusions of plasma from young donors, saying there is no evidence that they slow aging or memory loss, and can be dangerous.
Read more »
'Wacky' drug price system keeps costs high for patients paying for prescriptions, FDA Chief saysRebates are a favorite target of pharmaceutical companies, who say pharmaceutical benefit managers extract huge discounts but keep them for themselves instead of sharing the savings with patients.
Read more »
FDA plans first public hearings on legalizing CBD foods in AprilGottlieb said he has heard Congress 'loud and clear' when it legalized hemp products, including CBD, in December and is putting together a working group of senior officials to work on the new rules.
Read more »